Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 2:07 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 625–648 of 13,266 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Adult Disease Clear all

Conditions: Bipolar Disorder
Interventions: MCN36 (nutritional supplement), Placebo; Drug
Lead sponsor: University of Calgary; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: San Diego, California

Conditions: Depression Mild, Depressive Disorder, Major, Mild Cognitive Impairment
Interventions: Computerized Cognitive Remediation of Executive Functioning (CCR-EF), Active Control; Other
Lead sponsor: UConn Health; Other
Eligibility: 60 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Farmington, Connecticut

Conditions: Joint Dislocation, Perianal Abscess, Abscess
Interventions: Nitrous Oxide arm, Propofol, Oxygen; Drug
Lead sponsor: Albert Einstein Healthcare Network; Other
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Down Syndrome, Obstructive Sleep Apnea
Interventions: Not listed
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 1 Year to 90 Years
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2026
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: HIV Prevention, HIV Infections
Interventions: Tenofovir, HEC Placebo, Open label tenofovir tablet; Drug
Lead sponsor: CONRAD; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 2
States / cities: Los Angeles, California • Pittsburgh, Pennsylvania

Conditions: Cardiovascular Risk Reduction, Cardiovascular Risk
Interventions: CAN-DO; Behavioral
Lead sponsor: Martha Biddle; Other
Eligibility: 60 Years and older
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Localized Non-Resectable Adult Liver Carcinoma
Interventions: Yttrium-90 Resin Microspheres; Other
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 1,653 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 42
States / cities: Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 34 more

Conditions: Virus Diseases, RNA Virus Infections, Respiratory Tract Diseases, Respiratory Tract Infections
Interventions: Quadrivalent VLP Vaccine, Fluarix Quadrivalent® Comparator Vaccine; Biological
Lead sponsor: Medicago; Industry
Eligibility: 65 Years and older
Enrollment: 12,794 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 50
States / cities: Mobile, Alabama • Tempe, Arizona • Banning, California + 42 more

Conditions: Bipolar Disorder
Interventions: Not listed
Lead sponsor: Case Western Reserve University; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Fibromyalgia
Interventions: amino acid-based blend; Dietary Supplement
Lead sponsor: Pekarovics, Susan, MD; Other
Eligibility: 18 Years to 80 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Asthma
Interventions: AZD8630, Placebo, Inhaler; Drug · Device
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 537 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 45
States / cities: Mesa, Arizona • Huntington Beach, California • La Mesa, California + 41 more

Conditions: Leukemia, Myelodysplastic Syndromes
Interventions: filgrastim, sargramostim, cytarabine, daunorubicin hydrochloride, zosuquidar trihydrochloride, Placebo; Biological · Drug
Lead sponsor: Eastern Cooperative Oncology Group; Network
Eligibility: 60 Years and older
Enrollment: 449 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 91
States / cities: Scottsdale, Arizona • Aurora, Colorado • Boulder, Colorado + 67 more

Conditions: Obesity
Interventions: Time Restricted Eating (TRE); Behavioral
Lead sponsor: NYU Langone Health; Other
Eligibility: 25 Years to 65 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: Leukemia
Interventions: microarray analysis, molecular genetic technique, mutation analysis, polymerase chain reaction, reverse transcriptase-polymerase chain reaction, diagnostic laboratory biomarker analysis; Genetic · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 15 Years to 59 Years
Enrollment: 735 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Diabetes Mellitus, Chronic Obstructive Pulmonary Disease
Interventions: Subcutaneous Insulin, Inhaled Insulin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 30 Years to 77 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 77
States / cities: Glendale, Arizona • Peoria, Arizona • Phoenix, Arizona + 59 more

Conditions: Food Insecurity, Hypertension
Interventions: Food as Medicine Program, Survey; Behavioral · Other
Lead sponsor: Alison Gustafson; Other
Eligibility: 18 Years to 64 Years
Enrollment: 159 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Floyd, Kentucky

Conditions: Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Liver Cancer
Interventions: dolastatin 10; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2003
U.S. locations: 11
States / cities: Chicago, Illinois • Decatur, Illinois • Evanston, Illinois + 6 more

Conditions: Pulmonary Hypertension
Interventions: Ultrasound Doppler; Radiation
Lead sponsor: Echosense Ltd.; Industry
Eligibility: Not listed
Enrollment: 230 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2021
U.S. locations: 2
States / cities: Palo Alto, California

Conditions: Plaque Type Psorisis
Interventions: Tapinarof Cream 1%, VTAMA®, Placebo; Drug
Lead sponsor: Teva Pharmaceuticals USA; Industry
Eligibility: 18 Years and older
Enrollment: 560 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 26
States / cities: Scottsdale, Arizona • Bryant, Arkansas • Dublin, California + 20 more

Conditions: Breast Cancer, Cholangiocarcinoma, Colorectal Cancer, Head and Neck Neoplasms, Lymphoma, Large-Cell, Anaplastic, Melanoma, Neuroendocrine Tumors, Non-Small Cell Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Papillary Thyroid Cancer, Primary Brain Tumors, Renal Cell Carcinoma, Sarcomas, Salivary Gland Cancers, Adult Solid Tumor
Interventions: Entrectinib; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 534 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2027
U.S. locations: 48
States / cities: Phoenix, Arizona • Duarte, California • La Jolla, California + 32 more

Conditions: Cystic Fibrosis
Interventions: Inhaled AR-501, Inhaled Placebo; Drug
Lead sponsor: Aridis Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 102 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2023
U.S. locations: 25
States / cities: Tucson, Arizona • Long Beach, California • Denver, Colorado + 22 more

Conditions: Genetic Predisposition to Disease, Healthy Volunteers
Interventions: Sirolimus; Drug
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 45 Years to 65 Years
Enrollment: 205 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Acute Hypoxemic Respiratory Failure, High-Flow Nasal Cannula Therapy
Interventions: Protocolized HFNC Weaning Strategy, Usual Care HFNC Weaning; Behavioral
Lead sponsor: Rush University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Neoplasms, Triple-Negative Breast Cancer
Interventions: PF-06647263; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 10
States / cities: Boston, Massachusetts • Detroit, Michigan • Las Vegas, Nevada + 3 more

Search by objective public record fields.

Clinical Trial of a Nutritional Supplement in Adults With Bipolar Disorder

Cognitive Fitness for Depression in Older Adults

Adjunctive Nitrous Oxide During Emergency Department Propofol Sedation in Adults

Computer Models of Airways in Children and Young Adults With Sleep Apnea and Down Syndrome

Rectal Microbicide Safety and Acceptability Trial of Topically Applied Tenofovir Compared With Oral Tablet

A Community Cardiovascular Disease Risk Reduction Program in Older Adults Engaged in Congregate Nutrition Services (CAN-DO)

Yttrium Y 90 Resin Microspheres Data Collection in Unresectable Liver Cancer: the RESIN Study

Efficacy of a Plant-derived Quadrivalent Virus-like Particle (VLP) Vaccine in the Elderly

Personal Adherence Evaluation of Medication Use for Adult Bipolar Disorder Patients

Effect of an Amino-Acid-Based Blend on Human Growth Hormone (hGH) and Fibromyalgia (FM) Symptoms

A Dose Range-Finding Study to Assess the Efficacy and Safety of Multiple Dose Levels of AZD8630 in Adults With Uncontrolled Asthma at Risk of Exacerbations

Daunorubicin & Cytarabine +/- Zosuquidar inTreating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or Refractory Anemia

Time Restricted Eating for Weight Loss Maintenance

Genetics Study of Tissue Collected From Patients With Acute Myeloid Leukemia

A One Year Clinical Trial Assessing the Usefulness and Safety of Inhaled Insulin in Diabetics With COPD

Food Insecurity, Food as Medicine, Hypertension

Dolastatin 10 in Treating Patients With Metastatic Or Recurrent Liver, Bile Duct, or Gallbladder Cancer

Measurements and Characterization of Doppler Signals From the Right Chest in Pediatric and Adult Patients

Study Comparing Tapinarof Cream 1% To VTAMA ® (Tapinarof Cream 1%) In the Treatment of Plaque Psoriasis

Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)

SAD and MAD of Inhaled AR-501 in Health Adults and P. Aeruginosa Infected Cystic Fibrosis Subjects

This Study Consists of Two Study Parts Conducted Under a Single IRB. Part I: Short Term ApoE-dependent Cerebral Blood Flow Response to Sirolimus in Cognitively Normal Adults Part II: Short Term ApoE-dependent Cerebral Blood Flow and Lung Perfusion Response to Sirolimus in Cognitively Normal Adults

Protocolized Weaning of High-Flow Nasal Cannula in Adult Patients

A Study Of PF-06647263 In Patients With Advanced Solid Tumors